Oruka Therapeutics (NASDAQ:ORKA) Downgraded to “Sell” Rating by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other research analysts have also weighed in on ORKA. Barclays began coverage on Oruka Therapeutics in a research report on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. Guggenheim began coverage on shares of Oruka Therapeutics in a report on Monday, October 27th. They set a “buy” rating and a $60.00 target price on the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Thursday. They set a “buy” rating and a $45.00 price target on the stock. HC Wainwright decreased their price objective on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.14.

Oruka Therapeutics Price Performance

ORKA opened at $27.08 on Friday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -9.64 and a beta of -0.30. The business’s 50-day moving average price is $22.60 and its two-hundred day moving average price is $16.24. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $29.98.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. Sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics during the third quarter valued at about $39,000. Russell Investments Group Ltd. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at about $43,000. Legal & General Group Plc bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in Oruka Therapeutics during the 2nd quarter worth approximately $31,000. Finally, BNP Paribas Financial Markets raised its stake in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.